Embremma Injection 2 ml
₹17572.6*
MRP ₹21430
18% off
₹18215*
MRP ₹21430
15% CB
₹3215 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Provide Delivery Location
Embremma Injection 2 ml belongs to a group of medicines known as 'anti-cancer' used to treat various cancers, including breast and liposarcoma. Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. Breast cancer is cancer that forms in the cells of the breasts. A liposarcoma is a rare cancer that develops in your fatty tissue.
Embremma Injection 2 ml contains Eribulin, which works by stopping the cancer cells from separating into two new cells. So, it blocks the growth of the cancer.
Embremma Injection 2 ml should be administered to patients only in a hospital setting under the supervision of a physician qualified by training and experience to administer cancer chemotherapeutic agents. The most common adverse reactions that occur while on therapy are neutropenia (lower-than-normal levels of neutrophils), anaemia (lack of blood), asthenia (weakness), fatigue(tiredness), alopecia (hair loss), peripheral neuropathy (Weakness, numbness, and pain from nerve damage), nausea, and constipation. Most of these side effects of Embremma Injection 2 ml do not require medical attention and gradually resolve over time. However, if the side effects persist, contact your doctor.
To treat your condition effectually, continue taking Embremma Injection 2 ml for as long as your doctor has prescribed. Do not stop using the Embremma Injection 2 ml midway. It is expected to cause fetal harm when administered to a pregnant woman, so it should not be used in pregnant women. Both women and men using this Embremma Injection 2 ml should use birth control to avoid pregnancy. Discontinue nursing while on therapy, considering the importance of the drug to the mother. Caution should be exercised while using Embremma Injection 2 ml in patients with hepatic, renal, heart dysfunction and or Neutropenia (Lower-than-normal levels of neutrophils), so inform your doctor about all your medical conditions and medications you are currently taking.
Embremma Injection 2 ml contains Eribulin, which belongs to a group of medicines known as 'anti-cancer' used to treat various types of cancers, including breast and liposarcoma. It works by stopping the cancer cells from separating into two new cells. So, it blocks the growth of the cancer.
Before taking the Embremma Injection 2 ml, let your doctor know about all your allergic or hypersensitivity reactions to medicines or food. Before taking Embremma Injection 2 ml, inform your doctor about your medical history and other medications you are currently taking in order to rule out any potential negative effects. Embremma Injection 2 ml may cause permanent fertility problems in men if they take it. Please discuss this with their doctor before starting treatment. Women of childbearing age should use effective contraception during and up to 3 months after treatment with Embremma Injection 2 ml. Avoid the consumption of alcoholic beverages and grapefruit juices.
Drug-Drug Interactions: Embremma Injection 2 ml interacts with medicines used for irregular heartbeat (e.g. amiodarone), immunomodulatory medication (e.g. baricitinib, fingolimod), vaccinations (e.g. BCG Vaccine, mumps virus vaccine, rotavirus vaccine), antidepression medication (e.g. citalopram), antipsychotic medications (e.g. Clozapine).
Drug-Food Interactions: Do not drink grapefruit juice or alcoholic beverages while you are being treated with Embremma Injection 2 ml. It can affect the way the medicine works.
Drug-Disease Interactions: Embremma Injection 2 ml may potentially interact with various disease conditions, including infections (bacterial/fungal/protozoal/viral), severe hepatic and renal impairment and congenital long QT syndrome.
Cancer: Cancer is a condition where cells in a specific body part grow and reproduce uncontrollably. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. Cancer sometimes begins in one body part before spreading to other areas.
Breast cancer: It is a type of cancer that develops in breast cells stimulated by a female sex hormone called estrogen. Breast cancer may form in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and the fatty tissue or the fibrous connective tissue within the breast. The tumour cells invade other healthy breast cells and travel to lymph nodes, a primary pathway for the cancer cells to move to other body parts. Symptoms of breast cancer include a lump in the breast or tissue thickening, which feels different than the normal surrounding tissues, breast pain, redness, swelling, and nipple discharge other than breast milk.
Liposarcoma: Liposarcoma is a rare tumour derived from fat tissue that occurs in the “soft tissues” of the body (soft tissue sarcoma). It is classified as a cancer (malignant) because of its potential to recur locally and spread to other areas of the body. The severity of the disease depends on the subtype of the liposarcoma and the presenting stage of the primary tumour. It can arise in various locations throughout the body, although it is most frequently found in the extremities, particularly in the thigh.
Alcohol
Unsafe
Avoid alcohol consumption while on treatment with Embremma Injection 2 ml.
Pregnancy
Unsafe
Embremma Injection 2 ml should not be used during pregnancy because it can harm your fetus (newborn baby).
Breast Feeding
Unsafe
Do not breastfeed during this treatment because the medicine may pass into your milk. Doctors normally advise against breastfeeding throughout this treatment and for a certain period of time after the final medication is taken.
Driving
Caution
Embremma Injection 2 ml may cause side effects such as tiredness and dizziness. Do not drive or use machines if you feel tired or dizzy.
Liver
Caution
A lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (ChildPugh B) liver impairment. There is no information available on patients with severe liver impairment.
Kidney
Caution
A lower starting dose is recommended for patients with moderate (CrCl 30-50 mL/min) kidney impairment. There is no information available on patients with severe kidney impairment.
Children
Unsafe
Do not use this medicine for children between 0 to 18 years old.
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Product Substitutes